Please assess the completion status of the following clinical trial:

Trial Title: Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.~* Prior first line therapy with a platinum and taxane based combination as adjuvant therapy~* Measurable disease defined by RECIST criteria~* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.~* age \> 18~* Karnofsky performance status \> 70~* Up to three prior lines of cytotoxic therapy in the setting of recurrent disease.~* Estimated life expectancy of at least 3 months~* Women of child-bearing potential must have a negative pregnancy test~* Adequate hematopoietic function defined as:~  * ANC ≥ 1500/mm3~ * Platelets ≥ 100,000/mm3~ * Hemoglobin ≥ 9 g/dL~ * Magnesium ≥ lower limit of normal~ * Calcium ≥ lower limit of normal~* Adequate renal and hepatic function defined as:~  * Bilirubin ≤ 1.5 times upper limit of normal (ULN)~ * SGOT ≤ 3 times ULN~ * Alanine aminotransferase (ALT) ≤3xULN (if liver metastases ≤5xULN)~ * Alkaline phosphatase ≤ 3 times ULN~ * Creatinine ≤ 1.5 mg/dL times ULN~ * Creatinine clearance ≤ 50 mL/min~Exclusion Criteria:~* Prior anti-EGFr antibody therapy (e.g., cetuximab) or treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib)~* Prior treatment with gemcitabine~* Radiotherapy ≤ 14 days prior to enrollment.~* More than three lines of systemic chemotherapy for recurrent or advanced disease. Prior hormonal therapy is allowed.~* Prior immunotherapy, or experimental or approved proteins/antibodies~* Female subject is pregnant or breast-feeding.~* Patient has received other investigational drugs within 28 days before enrollment~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.~* Prior treatment with panitumumab~* Concurrent uncontrolled illness~* Ongoing or active infection~* History or active secondary cancer within the last 5 years, except for superficial basal cell skin cancers, curatively resected non-melanoma skin cancer~* Psychiatric illness or social situation that would preclude study compliance.~* History or known presence of central nervous system (CNS) metastasis~* Subjects requiring chronic use of immunosuppressive agents (e.g., methotrexate, cyclosporine)~* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) \< 1 year before randomization~* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any evidence of interstitial lung disease on baseline chest CT scan~* Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection~* Major surgery within 28 days or minor surgery within 14 days of study enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab and Gemcitabine (Type: EXPERIMENTAL): Panitumumab and Gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues